Adar1 Capital Management, Llc Portfolio Stock Holdings
According to the SEC 13F filed on August 14, 2026, Adar1 Capital Management, Llc disclosed 238 stock positions valued at approximately $2.13B as of quarter-end June 30, 2026. The largest holdings include ABIVAX SA, PROTAGONIST THERAPEUTICS INC, and ROIVANT SCIENCES LTD.
- Report Period
- June 30, 2026
- No. of Stocks
- 238
- Portfolio Value
- $2.13B
Holdings by Sector
Adar1 Capital Management, Llc Portfolio Holdings in Q2 2026
| Company | Symbol | Sector | Portfolio % | Shares | Change (Shares) | Change % | Value |
|---|---|---|---|---|---|---|---|
| ABIVAX SA | ABVX | Healthcare | 11.30% | 1,804,703 | +410,684 | +29.46% | $240,494,722 |
| PROTAGONIST THERAPEUTICS INC | PTGX | Healthcare | 5.54% | 960,863 | -33,256 | -3.35% | $117,782,587 |
| ROIVANT SCIENCES LTD | ROIV | Healthcare | 5.25% | 3,157,008 | -128,898 | -3.92% | $111,726,513 |
| STATE STR SPDR S&P 500 ETF T | SPY | Other | 4.53% | 129,087 | +53,147 | +69.99% | $96,398,299 |
| IMMUNOVANT INC | IMVT | Healthcare | 4.22% | 2,330,716 | -348,294 | -13.00% | $89,802,487 |
| ZAI LAB LTD | ZLAB | Healthcare | 3.01% | 3,369,034 | +1,943,667 | +136.36% | $64,011,646 |
| AGIOS PHARMACEUTICALS INC | AGIO | Healthcare | 2.25% | 1,288,053 | +1,147,381 | +815.64% | $47,799,647 |
| CRINETICS PHARMACEUTICALS IN | CRNX | Healthcare | 2.15% | 1,222,080 | +82,749 | +7.26% | $45,730,234 |
| EA SERIES TRUST | BOXX | Other | 1.86% | 337,125 | - | - | $39,473,966 |
| CYTOKINETICS INC | CYTK | Healthcare | 1.83% | 457,907 | -174,649 | -27.61% | $39,009,097 |
| SEPTERNA INC | SEPN | Other | 1.48% | 940,747 | -149,071 | -13.68% | $31,505,617 |
| ANTERIS TECHNOLOGIES GLOBAL | AVR | Other | 1.46% | 3,145,096 | -644,036 | -17.00% | $30,979,196 |
| EDITAS MEDICINE INC | EDIT | Healthcare | 1.35% | 8,889,000 | +8,889,000 | +100.00% | $28,800,360 |
| DENALI THERAPEUTICS INC | DNLI | Healthcare | 1.24% | 1,029,080 | -842,375 | -45.01% | $26,467,938 |
| SPYRE THERAPEUTICS INC | SYRE | Healthcare | 1.19% | 283,982 | -54,341 | -16.06% | $25,211,922 |
| VIR BIOTECHNOLOGY INC | VIR | Healthcare | 1.18% | 2,456,677 | -288,037 | -10.49% | $25,033,539 |
| PRAXIS PRECISION MEDICINES I | PRAX | Healthcare | 1.17% | 74,253 | +72,753 | +4850.20% | $24,859,162 |
| INSMED INC | INSM | Healthcare | 1.15% | 228,520 | +193,128 | +545.68% | $24,364,802 |
| CELLDEX THERAPEUTICS INC NEW | CLDX | Healthcare | 1.08% | 619,542 | +191,726 | +44.82% | $23,053,158 |
| VIKING THERAPEUTICS INC | VKTX | Healthcare | 1.05% | 574,038 | +346,321 | +152.08% | $22,393,222 |
| TAYSHA GENE THERAPIES INC | TSHA | Healthcare | 0.97% | 3,040,466 | +61,037 | +2.05% | $20,705,573 |
| MONOPAR THERAPEUTICS INC | MNPR | Other | 0.95% | 217,595 | -46,683 | -17.66% | $20,147,121 |
| OVID THERAPEUTICS INC | OVID | Healthcare | 0.94% | 7,417,479 | +2,873,366 | +63.23% | $19,953,019 |
| ENLIVEN THERAPEUTICS INC | ELVN | Healthcare | 0.92% | 387,718 | +58,178 | +17.65% | $19,676,689 |
| ENANTA PHARMACEUTICALS INC | ENTA | Healthcare | 0.92% | 1,344,510 | +1,293,153 | +2517.97% | $19,602,956 |
| NEKTAR THERAPEUTICS | NKTR | Other | 0.80% | 244,184 | +82,932 | +51.43% | $17,046,485 |
| INSPIRE MED SYS INC | INSP | Healthcare | 0.79% | 374,617 | -30,580 | -7.55% | $16,711,664 |
| REVOLUTION MEDICINES INC | RVMD | Healthcare | 0.77% | 87,509 | -46,384 | -34.64% | $16,388,686 |
| ESTABLISHMENT LABS HLDGS INC | ESTA | Other | 0.75% | 185,619 | -27,854 | -13.05% | $15,927,966 |
| RHYTHM PHARMACEUTICALS INC | RYTM | Healthcare | 0.71% | 136,158 | -75,292 | -35.61% | $15,117,623 |
Showing 30 of 238 holdings in the latest reporting period.
Adar1 Capital Management, Llc Options Holdings in Q2 2026
| Quarter | Symbol | Company | Option | Contracts | Notional Value |
|---|---|---|---|---|---|
| Q2 2026 | IWM | iShares Russell 2000 ETF | PUT | 62,500 | $18,778,125 |
| Q2 2026 | SPY | SPDR S&P 500 | PUT | 25,000 | $18,669,250 |
| Q2 2026 | XBI | SPDR Series Trust SPDR S&P Bio | PUT | 67,400 | $10,666,050 |
| Q2 2026 | ABVX | Abivax SA | CALL | 44,400 | $5,916,744 |
| Q2 2026 | AMLX | Amylyx Pharmaceuticals, Inc. | PUT | 40,100 | $720,196 |
| Q2 2026 | RARE | Ultragenyx Pharmaceutical Inc. | CALL | 20,000 | $667,800 |
| Q2 2026 | NVO | Novo Nordisk A/S | CALL | 13,000 | $623,220 |
| Q2 2026 | CRBP | Corbus Pharmaceuticals Holdings | CALL | 60,000 | $562,800 |
| Q2 2026 | STI | SOLIDION TECHNOLOGY INC | CALL | 13,500 | $125,415 |
Showing 9 of 9 options positions in the latest reporting period.
Notional value represents the total exposure of the options position.